Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603912 · ClinicalTrials.gov registry record · Phase 4
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
A Phase 4 study of Atrial Fibrillation, sponsored by Mina Chung, MD.
- Active
- Registry status
- Phase 4
- Development phase
- 175
- Enrollment target
- 1
- Study location
NCT03603912: Active Phase 4 study of Atrial Fibrillation, sponsored by Mina Chung, MD.
NCT03603912 is a Phase 4 study of Atrial Fibrillation that is active but no longer recruiting, run by Mina Chung, MD. The registered enrollment target is 175 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03603912, a Phase 4 study of Atrial Fibrillation, is active but no longer recruiting, sponsored by Mina Chung, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 175 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective randomized open-label blinded endpoint (PROBE) 2x2 factorial study of metformin extended release up to 750 mg BID and lifestyle and risk factor modification (LRFM) in CIED patients with at least 1 ≥5 minute episode of AF over the prior 3 months. Randomization will be stratified by pacemaker vs. ICD and rhythm at enrollment (sinus rhythm/atrial paced vs. AF).
Primary Outcome
Composite of change from baseline to 1 year of average daily AF burden % after a 3 month blanking period and survival at 1 year.
Conditions Studied
Interventions
- DRUG Metformin
- BEHAVIORAL Lifestyle/Risk Factor Modification
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2018-08-24 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What the registry record for NCT03603912 still lists
NCT03603912 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT03603912 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03603912 about?
NCT03603912 is a clinical study titled "Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)". Prospective randomized open-label blinded endpoint (PROBE) 2x2 factorial study of metformin extended release up to 750 mg BID and lifestyle and risk factor modification (LRFM) in CIED patients with at least 1 ≥5 minute episode of AF over the prior 3 months. Randomization will be stratified by pacema...
What is the current status of trial NCT03603912?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 175 participants. The study started on 2018-08-24. Estimated completion is 2026-12.
What conditions does trial NCT03603912 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT03603912?
The interventions under investigation include: Metformin (DRUG), Lifestyle/Risk Factor Modification (BEHAVIORAL).
Who is sponsoring clinical trial NCT03603912?
This trial is sponsored by Mina Chung, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03603912 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03603912's enrollment target sits among peer trials
175 110th of 202 higher than 92 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI